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rugs provide therapeutic benefits, ie, curing a
disease, slowing its evolution, or alleviating its symptoms,
but drugs also carry the risks of adverse drug reactions
(ADRs), which can span from frequent and minor symp-
toms, such as nausea or headache, to rare but severe
events, such as anaphylaxis, liver failure, or cancer. This
dual aspect of therapeutic interventions is seen beyond
pharmacology, for example in surgery with the risk of
complications such as hemorrhages or infections, and
even in psychotherapy, as psychotherapeutic interven-
tions sometimes induce aggravation of psychiatric symp-
toms. 
The review of the benefits and the risks associated with
a drug is called benefit:risk assessment (BRA), or bene-
fit-risk balance, or benefit:risk ratio evaluation. BRA is
basically an evaluation of two dimensions. The dimen-
sion of benefits is measured primarily in terms of thera-
peutic efficacy, ie, the successful treatment of the con-
dition for which the drug is indicated. There are other
types of benefits, such as improvement of quality of life
or pharmacoeconomic aspects, that are of interest in a
period where the costs of medicine are closely scruti-
nized. The dimension of risks includes the safety profile
observed in the form of the sum of all ADRs, but also
includes the potential risk of unobserved ADRs antici-
pated on the basis of the mechanism of action. 
The evaluation of the benefit:risk ratio of a drug is essen-
tial throughout the whole life cycle of a drug. During the
discovery phase, the analysis of the biological targets as
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Randomized evidence from clinical trials and natural-
istic evidence collected from pharmacoepidemiology
and pharmacovigilance activities both contribute to
the initial and continuous assessment of the benefits
and risks of a drug, ie, the balance between thera-
peutic efficacy and safety risks. Benefit-risk assessment
(BRA) mainly relies on a qualitative assessment of
quantitative data. Current attempts to quantify BRA
are reviewed and discussed, along with the expecta-
tions of regulatory authorities such as the Food and
Drug Administration and the European Medicines
Agency. No method provides a fully satisfactory solu-
tion regarding BRA, because it is difficult to reduce its
multidimensional aspect to simple metrics, in a context
where other therapeutic alternatives play a role.
Consistency and transparency are key in this assess-
ment, which is performed throughout the whole drug
life cycle. BRA is mainly based on randomized clinical
studies during clinical development, and it is contin-
ued and consolidated by naturalistic data once the
drug is on the market.  
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PAGES_12_AG_1003_BA.qxd:DCNS#49  31/05/11  0:16  Page 183well as medical chemistry will allow selection of lead mol-
ecules with the best BRA potential over hundreds of can-
didate molecules.
1,2 During the preclinical development of
the drug, the evidence obtained from animal models of
the disease is compared with the preclinical safety data
obtained from toxicological studies, and the preclinical
BRA will determine whether a candidate drug will be
administered for the first time in humans.
3 The BRA is
not a static process, and it evolves during the clinical
development, the registration process, and the marketing
period, when the drug is administered to patients.
However, at all times, BRA remains a major and complex
concept. In general, the dynamic aspects of BRA are due
to new findings that better characterize the safety profile
of a drug and sometimes uncover side effects, making the
safety profile of the drug less favorable. Drugs which have
been on the market for years can be withdrawn because
the revised safety evaluation confronted with the efficacy
findings, no longer supports a favorable BRA, even for
drugs with “blockbuster” status.
4
A revision of the BRA can be justified by the introduc-
tion of risk management measures such as a restriction
of the indication or monitoring measures. For example,
the multiple sclerosis monoclonal antibody natalizumab
was registered with significant restrictions in the target
patient population following suspension of clinical trials
due to some cases of severe infections.
Exceptionally, there are examples where unfavorable
BRAs have turned positive, for example when the dis-
covery of a new indication for an old drug increases the
positive aspects of its BRA: the relaunch of thalidomide
in the indications of multiple myeloma and erythema
nodosum leprosum is an example.
5
The above comments indicate that the BRA of a drug is
not an isolated exercise, since it occurs in a global med-
ical and pharmaceutical context. The type of indication
for which the drug is planned is critical in this assess-
ment. A drug with a safety profile including risks of
severe ADRs, potentially lethal, may be accepted in
oncology, but it should not be introduced for the treat-
ment of less severe disorders.
In absolute terms, the BRA of a drug is independent of
the existence of alternative therapeutics, but it is clear
that when other therapeutics are available in a given indi-
cation, regulatory authorities and prescribers will prefer
the drug with the more favorable BRA. Economic con-
siderations intervene here as well, and may influence this
value scale. 
In this review, we discuss the relative value for the BRA
based on evidence collected by randomized clinical tri-
als versus naturalistic studies. We adopt the following
definition of a naturalistic study: “a study in which the
researcher carefully observes and records some behav-
ior or phenomenon, sometimes over a prolonged period,
in its natural setting, while interfering as little as possi-
ble with the subjects or phenomena.”
6 The naturalistic
approach represents essentially all types of observations
which are not obtained in randomized clinical trials, but
which are obtained during the activities of pharma-
covigilance and pharmacoepidemiology. Based on the
different approaches used to create the BRA during the
life cycle of a drug and in the framework of drug regu-
lations, we discuss how both settings are of interest in
this assessment.
Naturalistic versus randomized evidence
During the first half of the 20th century, the evidence for
the therapeutic efficacy of new drugs, in particular anti-
infectious drugs, was often so obvious that the natural-
istic observations of therapeutic successes in treated
patients were sufficient to demonstrate efficacy.
However, soon the demonstration of the therapeutic
efficacy of new drugs became less obvious, and the need
to implement a methodology to demonstrate efficacy
appeared necessary.
7The demonstration of drug efficacy
is essentially a comparative exercise in which a new drug
is evaluated versus a comparator, a placebo, or a refer-
ence active drug. The clinical efficacy of a treatment is
assessed by clinical trials, the methodology of which has
been developed and perfected since the early experi-
ments of Sir Austin Bradford Hill in the 1950s
8; the cor-
nerstone of clinical trials is the randomization process
which ensures that groups of patients receiving the dif-
ferent treatments are similar. From a statistical view-
point, the demonstration of efficacy is based on the
rejection of the null hypothesis, ie, that there is no dif-
ference between the experimental and the comparator
treatments.
Several clinical trial designs are used during drug devel-
opment and generally a couple of randomized controlled
trials should provide a demonstration of the statistically
significant superiority of the experimental treatment
over the comparator. For example, the US Food and
Drug Administration (FDA) requires at least two phase
III pivotal trials with positive results to allow registra-
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9 Regulatory authorities such as the
European Committee for Medicinal Product for Human
Use (CHMP) from the European Medicines Agency
(EMA) regularly publish guidelines on how to evaluate
and demonstrate the efficacy and safety of drugs in dif-
ferent therapeutic indications, for example more than 20
CHMP guidelines set the framework for clinical devel-
opment and clinical trial methodology for neuropsychi-
atric drugs in Europe. Regulatory agencies rely essen-
tially on randomized controlled trials to support the
efficacy evidence. The establishment of efficacy is
achieved at the end of Phase III, when the results of the
pivotal trials which are key to support the registration
process are available. The efficacy conclusion for a given
indication will not be modified after this stage, although
replication of therapeutic efficacy studies sometimes
leads to disappointing results in comparison with those
from the pivotal trials.
10Any new observation of efficacy
in subgroups of patients by serendipity will need to be
confirmed by randomized evidence obtained in Phase
IIIb trials, in order to obtain an extension of the indica-
tion on the drug label. In the perspective of drug efficacy
demonstration, the naturalistic studies represent a
weaker design in terms of clinical and statistical quality
and power. Although a comparison between an active
treatment and a comparator can still be done in a natu-
ralistic setting, such a setting does not permit control for
all sources of bias in the estimation of efficacy because
of the absence of randomization. The randomized evi-
dence is the support for demonstrating the benefits
expected in BRA for the majority of drugs. There are
rare exceptions to this rule, either due to the scarcity of
cases or the terminal stage of an incurable illness, or
because of an imminent medical threat to the population
due to infectious agents,
11 which could justify omitting
proper clinical trials. In cases of threat of a pandemic
infectious disease, it could be necessary to market drugs
or vaccines despite limited information from random-
ized clinical trials; in such cases, there would also be lit-
tle to no information based on naturalistic observations,
and the decisions to administer the therapy in an emer-
gency would be based on surrogate outcomes. Another
situation where naturalistic observations might influence
the BRA would be when the efficacy of a drug, as
demonstrated in randomized clinical trials, did not seem
to be maintained in the clinical setting; for example, the
clinical benefit from psychotropic drugs seems to have
declined over the last decades. 
The evaluation of the safety profile of a drug is more com-
plex than the demonstration of its efficacy. Clinical trials
are designed and powered to demonstrate the efficacy of
the drug; although a lot of safety information is collected
during randomized trials, this information covers essentially
frequent ADRs, or more exactly the frequent adverse
events rather than drug reactions (as the causal relation-
ship between events and the taking of the drug is not yet
established). A minority of trials are designed specifically
for the assessment of safety, such as trials which assess ECG
changes due to drugs expected to affect cardiac electrical
conduction.
12 Indeed, the clinical development is limited in
terms of patient exposure and duration of exposure: only a
few thousand patients receive the drug during the clinical
development, most of these during a relatively short period.
Common ADRs can be identified during the clinical devel-
opment, but rare reactions, with frequency less than 0.1%,
are generally not identified. It will require the exposure of
10 000 patients or more in order to detect rare serious
ADRs.
13The randomized controlled trials performed dur-
ing Phases I to III do not have the power to properly assess
the full safety profile of a drug, and the safety profile of the
drug and its BRA established at the time of registration
remain limited by this difficulty to capture rare or/and
delayed ADR. During the post-registration period, phar-
macovigilance through spontaneous reports is critical to
consolidate the safety profile of the drug. However, the rar-
ity of spontaneous declarations by prescribers and the com-
plexity of assessing the causality of adverse events lead to
the idea that pharmacovigilance is insufficient to fully char-
acterize the BRA during the post-marketing period.
14
This can be complemented by pharmacoepidemiology
studies such as observational cohort studies, also called
post-approval safety studies in Europe,
15 where patients
are prescribed the drug of interest on purely medical
grounds, without any randomization. The pharmacovig-
ilance surveillance and the observational pharmacoepi-
demiology studies offer a naturalistic observational set-
ting which is essential to build the more comprehensive
safety profile post-registration and to confirm the pre-
registration BRA; the naturalistic setting plays a critical
role for marketed drugs. 
Quantitative methods for drug 
benefit-risk assessment
There is a growing interest in quantitative estimates of
the BRA,
16 and we review several quantitative and semi-
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these methods presents advantages and limitations,
meaning that so far none has received unanimous
approval nor is systematically used by regulatory author-
ities or by pharmaceutical industries. The methods pre-
sented provide an average BRA for a population of
patients, ie, they are not intended for a benefit-risk esti-
mation in individual patients. 
Number needed to treat
Number needed to treat (NNT) and number needed to
harm (NNH) are simple methods which are useful for
assessing the BRA in a single clinical trial.
17The NNT is
the number of patients who need to be treated with the
drug in order to achieve one more occurrence of effica-
cious treatment of the disease targeted by the drug. It is
not an absolute value—the NNT depends on the condi-
tions compared: experimental drug versus no treatment,
or a more or less efficacious alternative. The NNH means
the number of patients who need to be treated before one
more patient will experience an ADR. The NNH:NNT
ratio
18 is a simple tool to measure the increase in the num-
ber of therapeutic successes achieved for each additional
ADR incurred from using the drug of interest rather than
the reference treatment; it is a simple tool to assess the
benefit:risk ratio. If NNH:NNT is greater than 1, fewer
patients need to be treated to observe a benefit from the
drug than to have one additional occurrence of an ADR;
in other words the BRA is positive, at least numerically.
This metric is widely used by clinicians as well as reim-
bursement agencies or health insurances because of the
simplicity of the concept and its easy calculation. The
advantage of this approach is to use similar metrics for effi-
cacy and safety. However, it is questionable to compare
directly one therapeutic success versus one ADR. Indeed,
a therapeutic success of a drug can have a low clinical
impact, for example the decrease of the intensity of symp-
toms, whereas an ADR can be severe. Therefore, simply
counting the chance of one success versus the risk of one
ADR is simplistic. In addition, the risk profile of a drug
concerns several different ADRs, and such complexity is
difficult to summarize by just one single NNH value. 
In an attempt to account for the differences in the safety
profile, it is possible to take into account the patient util-
ity value of the outcome, ie, to consider patients’ prefer-
ence and quantify the preference for avoiding the dis-
ease of interest or a specific ADR.
19,20These utility scores
can be included in the NNH:NNT calculation. This
makes the calculation more complex and the relative
utility scores include some subjectivity.
Quality-Adjusted Time Without Symptoms and
Toxicity
Quality-Adjusted Time Without Symptoms and Toxicity
is a method where the time lost due to an ADR is sub-
tracted from the time gained from the treatment. In this
calculation, one can also use quality-adjusted life years
(QALYs), a measure of both the quality and the quan-
tity of life. Benefit is measured by drug-attributed gain
in QALYs, and the cumulative risks and disease pro-
gression are calculated to obtain drug-attributed loss of
QALYs.
21This approach allows direct comparison of the
gain (benefit) with the loss (risk) into a single metrics.
For an individual patient, this estimation can be valid,
but for a population of patients the attribution of the
value of a year of life gained or lost is more difficult, as
individual opinions diverge about this value. A some-
what similar approach is the incremental net health ben-
efit (INHB), where the method described above is used
in a comparative manner between two drugs.
22
Multi-Criteria Decision Analysis
Multi-Criteria Decision Analysis (MCDA) is a tool to
support decision-making where several benefits and
risks can be taken into account. This method had been
developed initially to support decision-making in the
domains of business and administration. In drug-related
MCDA, several risks measured by ADR, treatment dis-
continuations, drug/drug or drug/disease interactions can
be considered, while several benefits can be represented,
such as biochemical or clinical efficacy end points and
quality of life end points.
23,24The method is based on hier-
archical decision trees that include defined options with
different probabilities of occurrence. Different expected
performance scores are obtained, and the different
weighted scores for each option can be calculated.
Uncertainty parameters and sensitivity analyses can also
be computed in MCDA. This approach is promising as it
identifies which areas (risks or benefits) are more influ-
ential and need more scrutiny, allowing a more explicit
decision process. However, the model can be quite com-
plex and statistically tricky, and the assigned weights can
bring bias of subjectivity into the model.
Clinical research
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Other approaches have been proposed. In one of these,
25
a rectangle is formed by multiplying the strength of the
benefit (such as the magnitude of the positive efficacy
response) by the response rate. The rectangle is then
multiplied by the dimension (quantification) of evidence
to form a tridimensional efficacy cuboid. For a given
ADR, severity, frequency, and strength of evidence are
the three dimensions to construct the safety cuboid. The
positive benefit:risk ratio is demonstrated when the vol-
ume of the cuboid for benefits outbalances the sum of
all cuboids for the different ADRs. The advantage is that
different ADRs can be considered together. However, if
the concept is theoretically interesting, there is no prac-
tical way of comparing the benefit and risk cuboids, and
it is not certain that the volume represented by the sum
of ADRs can be geometrically compared with a volume
measuring the benefit of a drug. 
The methods mentioned above, despite their complex-
ity, still do not allow determination, in a simple way, of
the relative importance of the benefits and the risks of a
given drug in a specific indication. So far, they have not
replaced qualitative judgments by experts.
Regulatory authority views
The position of regulatory authorities on the BRA ques-
tion is instructive, because these authorities have the
dual objective of encouraging pharmaceutical thera-
peutic progress, while protecting public health.
Regulatory authorities rely essentially on qualitative
assessments and expert opinions. Quantitative methods
such as those presented above play only a supportive
role in the registration or drug surveillance process.
Relying on qualitative assessment and expert opinions
makes it necessary to ensure that the regulatory process
is valid, consistent, and transparent.
22 We present here
some aspects of the US and European regulatory
authorities’ approaches.
The FDA does not use a quantitative assessment of the
BRA, and relies on a qualitative assessment of the quan-
titative data collected during drug development. For the
FDA, the drug benefit derives from the efficacy end
points of clinical trials, and risks are based on adverse
events reported in trials and, once the drug is on the mar-
ket, on spontaneous safety data.
26The assessment is based
on a judgment where, in addition to the benefit and risks,
other factors enter into account such as the notion of
unmet medical need or the risk management plan pro-
posed to mitigate the potential safety risks of the drugs.
An important element in the BRA performed by the
FDA is the opinion given by the Advisory Committees
before drug registration, where different specialists inde-
pendent of the FDA, and sometimes also representatives
from patient groups, assess the drug dossier, and take a
decision by a vote. The committee decision is indicative,
the final decision being made by the FDA. The FDA qual-
itative assessment can be guided by a framework,
27 in a
way similar to that of the EMA. This framework supports
and formalizes the BRA judgment. It allows in particular
standardization of the consistency and transparency in the
BRA process and decision, which is essential for the pre-
scribers, the patients, and the pharmaceutical industry.
In Europe, the EMA published in 2008 a paper entitled
Reflection Paper on Benefit-Risk Assessment Methods in
the context of the Evaluation of Marketing Authorisation
Applications of Medicinal Products for Human Use.
28The
Agency explored approaches to improving the method-
ology for this assessment and the consistency and trans-
parency of the evaluations. For the EMA, as for the FDA,
assessments by experts are essential in BRA, and quan-
titative approaches do not yet replace this qualitative
assessment. Two main conclusions emerge from the
EMA paper. First, the Agency proposes the use of a spe-
cific template for the benefit-risk section of the drug
dossier, with specific guidance for the assessors. This guid-
ance allows summarization of the main data about ben-
efits and risks of the evaluated drug in a structured man-
ner. In particular, the BRA must be performed
considering the therapeutic context of the assessed drug.
The reflection paper also emphasizes the uncertainties
and variability of these estimations and their impact on
the decision. Second, it contains an acknowledgment of
the need to support research in the development of
quantitative or semiquantitative BRA methodologies.
The recently created European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance is part
of this initiative.
Clearly, the FDA and the EMA still rely on expert opin-
ions and qualitative assessment, and not yet on quanti-
tative methods, to summarize the evidence obtained in
clinical trials to construct the BRA prior to registration
of new drugs. But both agencies encourage the use of
frameworks to structure these assessments in order to
ensure consistency in the evaluation and decisions. 
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Contrary to the drug efficacy, for which statistical tests
can be used to demonstrate superiority of an experi-
mental drug over a comparator in a controlled study
design, the methodology to demonstrate in a definitive
way the safety of a treatment is less straightforward and
cannot be fully captured by randomized controlled study
design. For a given safety issue, the risk can be estimated
on the basis of incidences of ADR compared between
active and reference treatments; however, the safety pro-
file of a drug includes numerous safety issues, and it is
difficult to summarize this configuration into a one-
dimensional concept. Moreover, once the safety risks are
identified, in a benefit-risk perspective, one needs to
define the acceptance level for each of the risks. What is
the tolerated threshold incidence for a given severe
ADR such as a drug-induced hepatic failure: should one
accept an incidence of one case per 10 000 treated
patients, or one case per 100 000, or even less? The
response depends on the indication and efficacy of the
drug. To add to the difficulty, the efficacy of a drug is well
measured in randomized trials, while the risk of a spe-
cific ADR can only be assessed once this ADR has been
observed: as long as this is not the case, the ADR
remains hypothetical, based on some supposed biologi-
cal mechanism, or even ignored when the ADR is idio-
syncratic. For example, the risk of agranulocytosis with
clozapine became obvious when the first case series
were recorded,
29 not at the time of registration. The
potential for a given risk based on the known mecha-
nism of action of the drug (or on that of the pharmaco-
logical class of the drug) also enters into the balance, and
this potential risk can only be quantified with much
uncertainty.
The dimension of time is central to the evaluation of
risks, and the BRA of a drug starts during the preclini-
cal development, to continue during the clinical devel-
opment and the marketing phase. Once on the market,
the first years are critical for a drug BRA, as the expo-
sure to the new drug increases considerably in terms of
number of patients, of duration of exposure and of het-
erogeneity of patients compared with the selected
patient population included in the clinical trials.
However, even the first few years on the market are
sometimes not enough to establish a full BRA: the long-
term exposure can be critical, as certain ADR may be
observed only after an exposure of several years, such as
cancers or chronic organ toxicity. Immunodepression-
related lymphoproliferative disorders take about 5 years
to appear,
30 and liver cirrhosis may appear only after
decades of treatment with methotrexate.
31 Delayed tox-
icity can be observed in the offspring of patients exposed
to a drug, as seen with vaginal adenocarcinomas in
daughters of women who had taken diethylstilbestrol
during pregnancy.
32The information gathered from ran-
domized studies done during the clinical development
corresponds to a drug exposure of limited duration: at
this stage of development, the long-term exposure to the
drug (1 year or more) is restricted to a limited number
of patients—a few hundred. The International
Conference on Harmonisation (ICH) guideline E1a on
the long-term safety requires only 100 patients followed
up for 1 year in a registration dossier.
33 Only the natu-
ralistic observations of large-scale and long-duration
post-marketing exposure will bring the information on
rare and/or delayed ADR. The BRA, based on random-
ized evidence during the initial clinical development
phase, becomes mainly based on naturalistic evidence
during the post-marketing period, ie, on evidence from
pharmacoepidemiological observational studies and the
pharmacovigilance system.
The BRA remains mainly a qualitative exercise. An
important limitation inherent to all quantitative BRA
estimations is the level of subjectivity in estimating the
impact of the ADR, or of the safety risk. Certain BRA
quantitative methods use utility scores or patient pref-
erences in their computation. Such approaches are lim-
ited, as patient preferences are not available for all con-
ditions. Also patients suffering from a life-threatening
disorder such as cancer might not assess a given ADR
the same way as patients suffering from a less severe dis-
order such as depression. It is unclear to what extent one
could compare the utility-based approaches with a sub-
jective and individualized assessment to the evidence-
based appraisal of drugs. Another limitation of quanti-
tative BRA methods is the risk of oversimplification of
the parameters of the benefit:risk ratio; the NNH:NNT
ratio is an example of a mathematical tool too simple to
capture the complexity of the problem. 
This review focuses on the public health perspective, ie,
the BRA for the population of potential patients: this is
the view of the regulatory authorities and that of the
pharmaceutical industry. The BRA based on average
values represents what one could expect for the popu-
lation of patients (in clinical trials or pharmacoepidemi-
Clinical research
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Evaluación de la relación riesgo-beneficio 
de un fármaco mediante la evidencia 
randomizada y naturalística 
Tanto la evidencia de ensayos clínicos randomiza-
dos como la evidencia naturalística reunida a partir
de actividades farmacoepidemiológicas y de far-
macovigilancia contribuyen a la evaluación inicial y
continua de los beneficios y riesgos de un fármaco;
por ejemplo, el balance entre la eficacia terapéu-
tica y los riesgos en la seguridad. La evaluación
riesgo-beneficio (ERB) se basa principalmente en
una evaluación cualitativa de datos cuantitativos.
Se revisan y discuten los intentos actuales para
cuantificar la ERB, de acuerdo con las expectativas
de las autoridades reguladoras como la Food and
Drug Administration y la European Medicines
Agency. Ningún método proporciona una solución
totalmente satisfactoria en relación con la ERB, por-
que es difícil reducir su aspecto multidimensional a
una métrica simple, en un contexto donde juegan
un papel otras alternativas terapéuticas. La consis-
tencia y la transparencia son claves en esta evalua-
ción, la cual se realiza a través de todo el ciclo de
vida del fármaco. La ERB está basada principal-
mente en estudios clínicos randomizados durante
el desarrollo clínico y continúa y se consolida
mediante datos naturalísticos una vez que el fár-
maco está en el mercado.  
Évaluation du bénéfice-risque d'un 
médicament : données randomisées et 
naturalistiques
Les données randomisées des essais cliniques de
même que les données naturalistiques obtenues des
activités pharmacoépidémiologiques et de pharma-
covigilance contribuent à l’évaluation initiale et conti-
nue du bénéfice et des risques d’un médicament,
c'est-à-dire le rapport entre l’efficacité thérapeutique
et les risques de sécurité médicamenteuse.
L’évaluation du bénéfice-risque (EBR) repose princi-
palement sur l’évaluation qualitative de données
quantitatives. Les approches actuelles pour quantifier
l’EBR sont revues et discutées à la lumière des attentes
des autorités réglementaires telles que la Food and
Drug Administration et l’Agence Européenne du
Médicament. Aucune méthode n’apporte de solution
totalement satisfaisante à la problématique de l’EBR
car il est difficile de réduire l’aspect bidimensionnel
de l’EBR à une mesure simple, dans un contexte où
l’indication et les alternatives thérapeutiques jouent
un rôle essentiel. La cohérence et la transparence sont
des éléments clés dans cette évaluation qui est effec-
tuée tout au long du cycle de vie d’un médicament et
qui est principalement basée sur les études cliniques
randomisées durant le développement clinique et
consolidée par des données naturalistiques une fois
que le médicament est sur le marché. 
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